Integral Molecular offers rapid epitope mapping and phenotypic evaluation of antibody binding to SARS-CoV-2 Spike variants in line with FDA guidance
FDA Guidance for Anti-SARS-CoV-2 Monoclonal Antibodies1
- Characterize monoclonal antibody epitopes
- Identify antibody mechanism of action
- Phenotypically evaluate any prevalent variants with substitutions in or near the target epitope
1Development of Monoclonal Antibody Products Targeting SARSCoV-2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health Emergency. February 2021 (see guidance)
Got Antibodies? We can help.
In addition, our pseudotyped SARS-CoV-2 Reporter Virus Particles can help you safely assess (BSL2) the effect of variants on antibody neutralization
Integral Molecular does not work with any live viruses capable of causing infectious disease. We have developed Reporter Virus Particles (RVPs) to enable scientists to study viral components without the risk of exposure to viruses or the spread of contagious illnesses.